Navigation Links
Intravenous gene therapy protects normal tissue of mice during whole-body radiation

therapy administered intravenously could be used as an agent to protect vital organs and tissues from the effects of ionizing radiation in the event of large-scale exposure from a radiological or nuclear bomb, according to an animal study presented today by University of Pittsburgh researchers at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Philadelphia.

"Ionizing radiation can be extremely damaging to cells, tissues, organs and organ systems," said Joel S. Greenberger, M.D., professor and chairman department of radiation oncology, University of Pittsburgh School of Medicine. "In previous studies, we demonstrated that gene therapy can be both swallowed in pill form and inhaled through a nebulizer prior to radiation exposure to protect healthy tissues from damage. In this study, we found that the same therapy administered intravenously also offers protection during exposure to whole-body irradiation." Dr. Greenberger added that intravenous administration could potentially offer wide-reaching protection to the public in the event of a terrorist attack since experts believe a significant number of the population would die within 30 days of receiving a large dose of radiation to the entire body.

In the study, mice were used to test the protective effects of manganese superoxide dismutase plasmid liposome (MnSOD-PL) gene therapy on the bone marrow during whole-body irradiation. The researchers found that in a control group of mice that received an initial 9 Gy dose of radiation there was 80 percent survival at 30 days compared to 93.3 percent survival during the same length of time for an experimental group of mice that were injected with MnSOD-PL prior to irradiation. As the level of radiation exposure was increased, survival rates in the mice injected with MnSOD-PL prior to exposure increased significantly. For example, at 9.5 Gy, mice in the control group had a survival rate of 53 percent, while mic e in the experimental group had a survival rate of 87 percent. Following irradiation to 9.75 Gy, only 12.5 percent of the mice in the control group survived, while 75 percent of the MnSOD-PL group survived.

"Intravenous administration of gene therapy appears to prevent the damaging effects of radiation, suggesting it is a viable delivery method," said Dr. Greenberger. "Future clinical studies will tell us whether this therapy can protect people from the deadly effects of radiation."
'"/>

Source:University of Pittsburgh Medical Center


Related biology news :

1. Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
2. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
3. Columbia research lifts major hurdle to gene therapy for cancer
4. Combination therapy boosts effectiveness of telomere-directed cancer cell death
5. Gene therapy converts dead bone graft to new, living tissue
6. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
9. New therapy for HIV/AIDS eliminates needles and excessive toxicity
10. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
11. Gene therapy for Parkinsons disease moves forward in animals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... YORK , February 28, 2017 ... for avelumab  Prognosis for urothelial carcinoma is currently ... EMD Serono, the biopharmaceutical business of ... US and Canada , and Pfizer Inc. ... has accepted for Priority Review EMD Serono,s Biologics License Application ...
(Date:2/27/2017)... , Feb. 27, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced today the U.S. Food and Drug Administration ... (NDA) under section 505(b)(2) for DSUVIA™ (formerly ARX-04) ... of patients with moderate-to-severe acute pain in a ...
(Date:2/27/2017)... URBANDALE, Iowa (PRWEB) , ... February 27, 2017 , ... ... one of only a few in the Midwest offering premix services and private label ... poultry feed for laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has returned from her ... in several cities, she gained a number of delicious recipes and new techniques to ... in South Africa’s Western Cape province. It is internationally renowned for its incredible ...
Breaking Biology Technology: